Literature DB >> 18267309

Non-invasive prenatal diagnosis: public and patient perceptions.

Alastair Kent1.   

Abstract

The possibility of the application of reliable non-invasive prenatal diagnosis to clinical practice, and its likely availability as a tool for routine antenatal screening, is an important and exciting development that will be of interest to women and couples - especially where there is a known risk arising from family history, or some other source, of having a baby with a serious, disabling or life-limiting condition. Managing the introduction of this new technology will require attention to the understanding and perceptions of women, couples and the wider society, as well as to the clinical, scientific, technical and logistic issues that will inevitably arise.

Entities:  

Mesh:

Year:  2008        PMID: 18267309     DOI: 10.1016/j.siny.2007.12.009

Source DB:  PubMed          Journal:  Semin Fetal Neonatal Med        ISSN: 1744-165X            Impact factor:   3.926


  4 in total

1.  Demographic and experiential correlates of public attitudes towards cell-free fetal DNA screening.

Authors:  Lauren C Sayres; Megan Allyse; Taylor A Goodspeed; Mildred K Cho
Journal:  J Genet Couns       Date:  2014-04-09       Impact factor: 2.537

2.  Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation.

Authors:  Lauren C Sayres; Megan Allyse; Mary E Norton; Mildred K Cho
Journal:  Prenat Diagn       Date:  2011-07-27       Impact factor: 3.050

3.  What women want: lead considerations for current and future applications of noninvasive prenatal testing in prenatal care.

Authors:  Ruth M Farrell; Patricia K Agatisa; Benjamin Nutter
Journal:  Birth       Date:  2014-05-14       Impact factor: 3.689

4.  Motivations for undertaking DNA sequencing-based non-invasive prenatal testing for fetal aneuploidy: a qualitative study with early adopter patients in Hong Kong.

Authors:  Huso Yi; Nina Hallowell; Sian Griffiths; Tak Yeung Leung
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.